BioCryst Pharma (BCRX) Announces OPuS-2 Failed to Deliver Statistically Significant Results in HAE Attacks;
Tweet Send to a Friend
BioCryst Pharmaceuticals, Inc., (Nasdaq: BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial of avoralstat administered three times daily ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
